Serpin-resistant mutants of human tissue-type plasminogen activator
- 1 June 1989
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 339 (6227) , 721-724
- https://doi.org/10.1038/339721a0
Abstract
Tissue-type plasminogen activator (t-PA) converts the inactive zymogen, plasminogen, into the powerful protease, plasmin, which then degrades the fibrin meshwork of thrombi. To prevent systemic activation of plasminogen, plasma contains several inhibitors of t-PA, the most important of which is plasminogen activator inhibitor-1 (PAI-1), a member of the serpin superfamily. As the ability to produce serpin-resistant variants of t-PA could increase the potential of this enzyme as a thrombolytic agent, we have used the known three-dimensional structure of the complex between trypsin and bovine pancreatic trypsin inhibitor (BPTI) to model the interactions between the active site of human t-PA and PAI-1. On the basis of this model we then altered by site-directed mutagenesis those amino acids of t-PA predicted to make contact with PAI-1 but not with the substrate plasminogen. We report here that although the resulting mutants have enzymatic properties similar to those of wild-type t-PA, they display significant resistance to inhibition by PAI-1. For example, following incubation with an amount of the serpin that completely inhibits the wild-type enzyme, one variant retains 95% of its initial activity. This mutant is also resistant to inhibition by the complex mixture of serpins present in human plasma.Keywords
This publication has 28 references indexed in Scilit:
- Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activatorArchives of Biochemistry and Biophysics, 1988
- Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.Circulation, 1988
- Knowledge-based prediction of protein structures and the design of novel moleculesNature, 1987
- cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.Journal of Clinical Investigation, 1986
- Thrombolytic therapy in the eightiesBlood, 1986
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Tissue Plasminogen Activator: Chemical and Physiological AspectsSeminars in Thrombosis and Hemostasis, 1984
- Adaptation of plasminogen activator sequences to known protease structuresFEBS Letters, 1983
- HUMAN PLASMA PROTEINASE INHIBITORSAnnual Review of Biochemistry, 1983
- Enzymatic properties of the one-and two-chain form of tissue plasminogen activatorThrombosis Research, 1982